NLS Pharmaceutics AG (NLSP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NLS Pharmaceutics AG (NLSP) has a cash flow conversion efficiency ratio of -0.719x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.07 Million) by net assets ($2.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see NLS Pharmaceutics AG market capitalisation for the company's overall valuation and market capitalisation.
NLS Pharmaceutics AG - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how NLS Pharmaceutics AG's cash flow conversion efficiency has evolved over time, based on yearly financial data.
NLS Pharmaceutics AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NLS Pharmaceutics AG ranked by their cash flow conversion efficiency. Explore NLSP cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Duksung Co Ltd
KO:004835
|
0.003x |
|
THALASSA HLDG.NEW DL-01
F:TH2P
|
N/A |
|
Svenska Aerogel Holding AB (publ)
ST:AERO
|
-0.184x |
|
Oriental Trimex Limited
NSE:ORIENTALTL
|
0.008x |
|
Wi2Wi Corporation
V:YTY
|
-0.128x |
|
Odyssean Investment Trust PLC
LSE:OIT
|
0.000x |
|
The GYM Group PLC
LSE:GYM
|
0.318x |
|
EVE Health Group Limited
AU:EVE
|
-0.242x |
Annual Cash Flow Conversion Efficiency for NLS Pharmaceutics AG (2017–2024)
The table below shows the annual cash flow conversion efficiency of NLS Pharmaceutics AG from 2017 to 2024. View current stock price of NLS Pharmaceutics AG for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.41 Million | $-4.27 Million | -3.035x | -376.81% |
| 2023-12-31 | $-8.83 Million | $-9.68 Million | 1.096x | +125.92% |
| 2022-12-31 | $3.28 Million | $-13.88 Million | -4.230x | +84.64% |
| 2021-12-31 | $542.39K | $-14.94 Million | -27.538x | -34018.81% |
| 2020-12-31 | $-8.98 Million | $-729.39K | 0.081x | +163.67% |
| 2019-12-31 | $-6.17 Million | $-190.01K | 0.031x | -90.07% |
| 2018-12-31 | $-8.81 Million | $-2.73 Million | 0.310x | -55.95% |
| 2017-12-31 | $-7.72 Million | $-5.43 Million | 0.704x | -- |
About NLS Pharmaceutics AG
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity … Read more